Online Inquiry

Verification code

Peptide Process Development

Bioactive peptides are protein hydrolysates that induce positive physiological responses when introduced into the human body. However, the development of peptide leads into commercial drugs is a very challenging and time-consuming process. Peptides usually have poor in vivo stability, poor pharmacokinetics and bioavailability. For most therapies, orally administered compounds are preferred and developing compounds that maintain the initial bioactivity of the peptide lead while having good bioavailability and pharmacokinetic profiles is very difficult and requires substantial chemical support. As experts in the manufacture of complex and high quality peptides, BOC Sciences continues to make significant technological advances to support your research and development programs. As a reliable GMP peptide manufacturing partner throughout the peptide process development lifecycle, our team has established industry-leading capabilities and capacity, and has built a reputation for developing fit-for-purpose processes that will ensure the success of your drug development program.

A modular view of  the peptide drug development cycle. Figure 1. A modular view of the peptide drug development cycle. (Lee, C. L.; Harris, J. L. et al. 2019)

Our Services

To make it easier and better for researchers, BOC Sciences provides peptide process development service in a competitive fashion. We have provided a more efficient way to increase the number of new drugs, greatly shorten the R&D cycle, and reduce the development costs.

Key steps in developing peptides drug candidates

  1. Optimization of peptides
  2. BOC Sciences utilizes the capabilities of peptide libraries to explore optimization of potency and selectivity while reducing the size required for activity. The structure-activity relationships established are critical for the development of peptidomimetics and small molecules later in the project

  3. Peptidomimetic development
  4. By employing the information obtained from peptide optimization, our professional peptide team has offered a diversity of modifications services, including bioisosteres, modified terminal endings, and amino acid modifications, to improve the stability, bioavailability and pharmacokinetics of the lead compound

  5. Peptides lead optimization (medicinal chemistry)
  6. We use the knowledge gained from the previous two phases to develop small molecule mimics. We have strong experience in the optimization phase of medicinal chemistry programs to advance small molecules to preclinical drug candidates

Comprehensive peptide process development capabilities

a. Extensive peptide process development

  • Linear peptides
  • Cyclic peptides
  • Modified peptides

b. Capabilities in solid phase and liquid phase chemistry

c. Peptide conjugation, such as PPMO and peptide-toxin conjugation

Development of  peptide and small molecule binding GPCRs. Figure 2. Development of peptide and small molecule binding GPCRs. (Steffen, W.; Stefan, G. et al. 2015)

GMP manufacturing capabilities

  • With our global standard quality system, we can provide you with a reliable, cost-effective, and long-term supply of peptide APIs from gram to metric ton scale
  • Our unique "one-stop-shop" platform ensures knowledge retention and seamless scalability throughout the product lifecycle, and accelerates your development by eliminating the need for multi companies/sites transfer
  • Streamlined process development, scale-up and large-scale manufacture

Liquid phase peptide synthesis

  • Process development and production of a wide range of peptide molecules
  • Cyclic and disulfide bridge structures
  • Continuous flow extraction and hydrogenation technologies
  • Dedicated process crystallization team

Features of Our Peptide Services

  • BOC Sciences offers unique chemistry skills to help advance your peptide hit into a potential drug ready for preclinical testing in a cost and time efficient manner
  • We offer complete peptide and protein services, from process development to GMP production, from early stage to commercial launch
  • BOC Sciences has developed an industry-leading process development team of over 2,000 scientists and state-of-the-art facilities. Together with our small molecule team, we will provide sufficient capacity and flexibility to better meet your needs

Schematic illustration of  (a) the formation of peptide-based supramolecular hydrogels. Figure 3. Schematic illustration of (a) the formation of peptide-based supramolecular hydrogels. (Yi, L.; Wang, F. et al. 2016)

Why choose BOC Sciences?

Our dedicated CMC team has provided tailored solutions to our clients from engagement to launch. With many years of industry experience, we provide clients with the following:

  • Comprehensive, integrated CMC services with a flexible service model that grows with your programs
  • Knowledgeable industry experts who deliver scalable, actionable insights
  • World-class facilities and equipment that remain at the forefront of the global pharmaceutical research, analytical and development standards
  • Our comprehensive services support products at every stage of the product lifecycle, from early-stage discovery to full commercial cGMP manufacture
  • A focus on risk management that is designed to ensure completion of your technical goals

BOC Sciences provides professional, rapid and high-quality services of peptide process development at competitive prices for global customers. Personalized and customized services of peptide process development can satisfy any innovative scientific study demands. Our clients have direct access to our staff and prompt feedback to their inquiries. If you are interested in our services, please contact us immediately!


  1. Lee, C. L.; Harris, J. L. et al. A Comprehensive Review on Current Advances in Peptide Drug Development and Design. International Journal of Molecular Sciences. 2019. 20(10).
  2. Steffen, W.; Stefan, G. et al. Sequence, Structure and Ligand Binding Evolution of Rhodopsin-Like G Protein-Coupled Receptors: A Crystal Structure-Based Phylogenetic Analysis. Plos One. 2015. 10(4): e0123533.
  3. Yi, L.; Wang, F. et al. Peptide‐based supramolecular hydrogels for delivery of biologics. Bioengineering & Translational Medicine. 2016. 1(3): 306-322.


Copyright ©  2024  BOC Sciences. All rights reserved.